Diligence memo · auto-generated · as of July 3, 2026
Ocular Therapeutix, Inc
Ocular Therapeutix, Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Ocular Therapeutix, Inc operates in Biotechnology, based in BEDFORD.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ocular Therapeutix, Inc has raised $81M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $38M on 2019-03-01.
Most recent recorded round closed around 2019-03-01.
Valuation (modeled)modeled
Provath models Ocular Therapeutix, Inc at approximately $1.5B (range $75M–$5.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.42× the median modeled value of Series B Biotechnology companies in 2019–2021 (118 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 25 months.
Last raise 7.3 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 88% of Biotechnology peers (4293 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: Pandion Therapeutics Holdco LLC, Insilico Medicine Cayman TopCo, Purigen Biosystems, Inc., Lucira Health, Inc., Peptilogics, Inc..
Peoplefiled
23 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.